TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21375382

Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PV)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT)
Number of subjects: 82
Study: 18786624

Group type: EXPERIMENTAL
Intervention: UDB 0.06 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: UDB 0.12 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: UDB 0.24 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Commercial budesonide 0.25 mg
Number of subjects: 16
Study: 17530263

Group type: EXPERIMENTAL
Intervention: Laparoscopic colorectal resection
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional colorectal resection
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Overall morbidity
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Local morbidity
Number of subjects: 28

Group type: COMPARATOR
Intervention: High-quality RCT (E & P > 70)
Number of subjects: 28
Study: 15791100

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (100 mg/kg before incision and 10 mg/kg/h during surgery)
Number of subjects: 44

Group type: COMPARATOR
Intervention: 0.9% saline (placebo)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 44
Study: 11809113

Group type: EXPERIMENTAL
Intervention: Octreotide (0.1 mg IV injection + continuous drip at 25 microg/h for 24 hours)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Octreotide (0.1 mg IV injection + continuous drip at 42 microg/h for 24 hours)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Omeprazole (40 mg IV injection + continuous drip at 8 mg/h for 24 hours)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Octreotide (same dosage as in group 1 for 72 hours)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Omeprazole (same dosage as in group 3 for 72 hours)
Number of subjects: 24
Study: 9275134

Group type: EXPERIMENTAL
Intervention: Olfactory function evaluation using a modified Connecticut Chemosensory Clinical Research Center testing procedure for threshold, identification, and discrimination
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Nasal eosinophilic inflammation measured by eosinophil cationic protein (ECP) in nasal secretions
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Nasal volume flow (NVF) measurement
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (12 volunteers without allergy)
Number of subjects: 17
Study: 7936562

Group type: EXPERIMENTAL
Intervention: Surgery (trabeculectomy)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Medicine
Number of subjects: 168

Group type: COMPARATOR
Intervention: Laser
Number of subjects: 168
Study: 2896866

Group type: EXPERIMENTAL
Intervention: Intravenous desferrioxamine 1 g at the end of each dialysis for six months
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 16
Study: 31648655

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 29644465

Group type: EXPERIMENTAL
Intervention: Mentored group (one-to-one tutoring)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (video material from SAGES)
Number of subjects: 60
Study: 28814805

Group type: EXPERIMENTAL
Intervention: Intercalating gefitinib (250 mg/day on days 15-25 of each cycle until disease progression)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Chemotherapy (gemcitabine 1250 mg/m2 plus carboplatin 5 AUC)
Number of subjects: 219
Study: 26598478

Group type: EXPERIMENTAL
Intervention: Asenapine 2.5 mg b.i.d.
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Asenapine 5 mg b.i.d.
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Asenapine 10 mg b.i.d.
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Asenapine (all doses)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 403
Study: 23578031

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 100/25 μg
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 200/25 μg
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185

Group type: COMPARATOR
Intervention: Prednisolone 10 mg daily
Number of subjects: 185
Study: 22089446

Group type: EXPERIMENTAL
Intervention: Higher protein (HP) diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lower protein (LP) diet
Number of subjects: 0
Study: 19692802

Group type: EXPERIMENTAL
Intervention: Peroperatively applied local doses of a mix containing corticosteroids
Number of subjects: 200

Group type: COMPARATOR
Intervention: No corticosteroid treatment (control group)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups (steroid and control)
Number of subjects: 200
Study: 16987866

Group type: COMPARATOR
Intervention: Lamivudine monotherapy (100 mg per day for 48 weeks)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Sequential treatment with lamivudine (100 mg per day for 20 weeks) followed by interferon‐alpha‐2b (5 million units three times per week for 4 weeks, then 5 million units three times per week for another 24 weeks)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Lamivudine monotherapy
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Sequential treatment
Number of subjects: 162
Study: 15454274

Group type: EXPERIMENTAL
Intervention: Dark chocolate (DC group)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: High-polyphenol chocolate (HPC group)
Number of subjects: 45

Group type: COMPARATOR
Intervention: White chocolate (WC group)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All groups (DC, HPC, WC)
Number of subjects: 45
Study: 10927061

Group type: EXPERIMENTAL
Intervention: Modified hysterosalpingography (1-2 mL of water-soluble contrast medium followed by 10 mL of saline)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard hysterosalpingography (undiluted contrast medium)
Number of subjects: 78
Study: 8829934

Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia (TIVA) with a propofol and alfentanil mixture
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard inhalational technique
Number of subjects: 30
Study: 2003707

Group type: COMPARATOR
Intervention: Single cycle of perioperative chemotherapy (cyclophosphamide, methotrexate, fluorouracil, leucovorin)
Number of subjects: 1229

Group type: EXPERIMENTAL
Intervention: Six cycles of conventionally timed chemotherapy (cyclophosphamide, methotrexate, fluorouracil, prednisone) for premenopausal women or this combination plus tamoxifen for postmenopausal women
Number of subjects: 1229

Group type: EXPERIMENTAL
Intervention: Both perioperative and conventionally timed chemotherapy for a 7-month course of adjuvant therapy
Number of subjects: 1229
Study: 6391232

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Antacid
Number of subjects: 100
Study: 28815316

Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Baseline QoL factors
Number of subjects: 147
Study: 27388365

Group type: EXPERIMENTAL
Intervention: Moderately unhealthy oral conditions based on OHAT scores
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Unhealthy oral conditions based on OHAT scores
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Moderate-to-very poor oral hygiene assessed by PI
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Overall oral health status
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: VAP incidence
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Number of teeth
Number of subjects: 162
Study: 25961461

Group type: COMPARATOR
Intervention: 100 mg anacetrapib with background treatment of placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 100 mg anacetrapib with background treatment of 20 mg atorvastatin
Number of subjects: 39
Study: 23986331

Group type: EXPERIMENTAL
Intervention: Scaling/root planing with Perioscope™
Number of subjects: 30

Group type: COMPARATOR
Intervention: Scaling/root planing without Perioscope™
Number of subjects: 30
Study: 20402755

Group type: EXPERIMENTAL
Intervention: 5‐Hz ipsi‐lesional rTMS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1‐Hz contra‐lesional rTMS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 60
Study: 18628448

Group type: EXPERIMENTAL
Intervention: Targeted design randomizing patients with appropriate marker status
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomizing all patients regardless of marker values
Number of subjects: 0
Study: 16001165

Group type: EXPERIMENTAL
Intervention: Oral vinorelbine 70 mg/m2
Number of subjects: 27

Group type: COMPARATOR
Intervention: Intravenous vinorelbine 30 mg/m2
Number of subjects: 27
Study: 12581972

Group type: COMPARATOR
Intervention: 2.0 mg/ml ropivacaine (group R)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.25 mg/ml ropivacaine plus 1.0 microg/ml fentanyl (group RF1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.0 mg/ml ropivacaine plus 2.0 microg/ml fentanyl (group RF2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.0 mg/ml ropivacaine plus 4.0 microg/ml fentanyl (group RF4)
Number of subjects: 60
Study: 10102744

Group type: EXPERIMENTAL
Intervention: Nabers probe
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pressure‐calibrated plastic probe (TPS)
Number of subjects: 10
Study: 7776420

Group type: EXPERIMENTAL
Intervention: Rufloxacin 200 mg once daily (after a loading dose of 400 mg on day 1)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg twice daily
Number of subjects: 110
Study: 2149210

Group type: EXPERIMENTAL
Intervention: Calisthenics program (CAL) for 3 months with biweekly sessions of flexion exercises
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Back school program (5 sessions)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 142
Study: 388407

Group type: EXPERIMENTAL
Intervention: Breathing 100 ppm of carbon monoxide (mean venous carboxyhemoglobin level raised from 1.42 to 3.90%)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Compressed, purified air (mean carboxyhemoglobin level decreased from 1.43 to 1.26%)
Number of subjects: 20
Study: 30298757

Group type: EXPERIMENTAL
Intervention: Positive nonverbal feedback
Number of subjects: 130

Group type: COMPARATOR
Intervention: Negative nonverbal feedback
Number of subjects: 130
Study: 26522053

Group type: EXPERIMENTAL
Intervention: MTD doxorubicin (MTD-DOX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination DOX/mCTX
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-agent DOX
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (dogs receiving DOX alone)
Number of subjects: 0
Study: 25873274

Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo procedure
Number of subjects: 0
Study: 24013941

Group type: EXPERIMENTAL
Intervention: BFRT low volume (BFRT LV)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: BFRT high volume (BFRT HV)
Number of subjects: 35

Group type: COMPARATOR
Intervention: HIT
Number of subjects: 35
Study: 21342768

Group type: EXPERIMENTAL
Intervention: Papillary muscle approximation (PMA) combined with ventriculoplasty
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (ventriculoplasty without PMA)
Number of subjects: 30
Study: 19728220

Group type: EXPERIMENTAL
Intervention: 12-week home-based exercise program
Number of subjects: 88

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 88
Study: 17584355

Group type: EXPERIMENTAL
Intervention: Nurse's education using short message service (SMS) for 12 weeks, including diet, exercise, medication adjustment, and self-monitoring of blood glucose levels.
Number of subjects: 51

Group type: COMPARATOR
Intervention: Nurse's education using short message service (SMS) for 12 weeks.
Number of subjects: 51
Study: 15189746

Group type: EXPERIMENTAL
Intervention: Meropenem 125 mg/h
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Meropenem 250 mg/h
Number of subjects: 7

Group type: COMPARATOR
Intervention: Meropenem 125 mg/h and 250 mg/h
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Meropenem continuous infusion
Number of subjects: 7
Study: 11245536

Group type: EXPERIMENTAL
Intervention: Tourniquet inflated at high pressure (about 350 mmHg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Tourniquet inflated at low pressure (about 225 mmHg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: No tourniquet
Number of subjects: 31
Study: 9605374

Group type: EXPERIMENTAL
Intervention: MNS technique (4 injections of 10 mL each)
Number of subjects: 100

Group type: COMPARATOR
Intervention: TA technique (2 injections of 20 mL each)
Number of subjects: 100
Study: 8986187

Group type: EXPERIMENTAL
Intervention: Ringer's solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haemaccel
Number of subjects: 0
Study: 2258780

Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo phases
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active treatment phases
Number of subjects: 0
Study: 7374099

Group type: COMPARATOR
Intervention: Isotonic electrolyte solution (control)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Bisacodyl
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Deoxycholic acid (high concentration)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Meproscillarin
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Digitoxin
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Rhein
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Cholic acid
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Oleic acid
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Ricinoleic acid
Number of subjects: 83
Study: 30551540

Group type: EXPERIMENTAL
Intervention: Topical emulgel formulation with Mimosa pudica seed extract
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29020976

Group type: EXPERIMENTAL
Intervention: Supporting LIFE electronic Community Case Management Application (SL eCCM App)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Paper-based Community Case Management (paper-CCM)
Number of subjects: 102
Study: 26231464

Group type: EXPERIMENTAL
Intervention: Uterus transplantation (UTx)
Number of subjects: 9
Study: 23607537

Group type: EXPERIMENTAL
Intervention: Standard behavioural weight loss programme (BWLP)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Stepped-down approach
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Greater self-monitoring
Number of subjects: 52
Study: 20950166

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 μg daily injections)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 18769244

Group type: EXPERIMENTAL
Intervention: Modern trial methodology and appropriate outcome measurements
Number of subjects: 0
Study: 16365057

Group type: EXPERIMENTAL
Intervention: Tempeh (mainly isoflavone aglycon)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Textured vegetable protein (predominantly isoflavone glucosides)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Soy milk
Number of subjects: 59
Study: 14616834

Group type: EXPERIMENTAL
Intervention: Patients with RAS
Number of subjects: 22

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 22
Study: 11027753

Group type: EXPERIMENTAL
Intervention: Arthroscopic debridement and fenestration of the olecranon fossa
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: O-K procedure
Number of subjects: 44

Group type: COMPARATOR
Intervention: Both procedures
Number of subjects: 44
Study: 8913140

Group type: EXPERIMENTAL
Intervention: Intramedullary nailing
Number of subjects: 2

Group type: COMPARATOR
Intervention: External fixation
Number of subjects: 2

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 2
Study: 1958279

Group type: EXPERIMENTAL
Intervention: Triple therapy (low-dose cyclosporin, azathioprine, methylprednisolone)
Number of subjects: 102

Group type: COMPARATOR
Intervention: CyA plus MP (double drug combination)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Aza plus CyA (double drug combination)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Aza plus MP (double drug combination)
Number of subjects: 102
Study: 6184564

Group type: COMPARATOR
Intervention: Nifedipine (10 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Nifedipine (20 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Captopril (1 mg/kg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 19
Study: 30565955

Group type: EXPERIMENTAL
Intervention: Comprehensive intervention implemented in 6 schools for 1 year.
Number of subjects: 1889

Group type: COMPARATOR
Intervention: Control group (6 schools, no intervention).
Number of subjects: 1889

Group type: EXPERIMENTAL
Intervention: Comprehensive intervention.
Number of subjects: 1889
Study: 27531122

Group type: EXPERIMENTAL
Intervention: Social importance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Promising a reward
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both social importance and promising a reward
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard prospective memory instructions (control condition)
Number of subjects: 0
Study: 26031399

Group type: EXPERIMENTAL
Intervention: Ultrasound at 36 weeks' gestation
Number of subjects: 2586

Group type: COMPARATOR
Intervention: Ultrasound at 32 weeks' gestation
Number of subjects: 2586

Group type: EXPERIMENTAL
Intervention: Emergency Cesarean delivery for fetal distress
Number of subjects: 2586

Group type: EXPERIMENTAL
Intervention: Neonatal admission
Number of subjects: 2586

Group type: EXPERIMENTAL
Intervention: Hypoglycemia
Number of subjects: 2586

Group type: EXPERIMENTAL
Intervention: Hyperbilirubinemia
Number of subjects: 2586
Study: 24321403

Group type: EXPERIMENTAL
Intervention: Text messages for medication reminders and education
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Educational text messages only
Number of subjects: 90

Group type: COMPARATOR
Intervention: No text messages
Number of subjects: 90
Study: 22206078

Group type: EXPERIMENTAL
Intervention: 1064 nm Nd:YAG laser hair reduction
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (contralateral axilla)
Number of subjects: 6
Study: 20201481

Group type: EXPERIMENTAL
Intervention: New oral anticoagulants (direct thrombin inhibitors and direct factor Xa inhibitors)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional anticoagulants (warfarin and low-molecular-weight heparins)
Number of subjects: 0
Study: 17314693

Group type: EXPERIMENTAL
Intervention: Dobutamine (20 microg/kg/min)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Dopamine (20 microg/kg/min)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Dopamine (10 microg/kg/min)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Dobutamine (10 microg/kg/min)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 106
Study: 15083370

Group type: EXPERIMENTAL
Intervention: Unloaded (UL) breathing conditions
Number of subjects: 7

Group type: COMPARATOR
Intervention: Normal (CON) breathing conditions
Number of subjects: 7
Study: 11435508

Group type: EXPERIMENTAL
Intervention: Gamma-linolenic acid (GLA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fish oil (FO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid (ALNA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arachidonic acid (ARA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)
Number of subjects: 0
Study: 10399110

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg orally once daily (n = 119)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Clarithromycin 500 mg orally twice daily (n = 117)
Number of subjects: 236
Study: 11271223

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 3354734

Group type: EXPERIMENTAL
Intervention: One-session class in breast self-examination (BSE)
Number of subjects: 459
Study: 30606112

Group type: EXPERIMENTAL
Intervention: Computerised dynamic posturography (CDP)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Mobile vibrotactile posturography system
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation (VR) protocols
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Timed up and go test
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: CDP scores
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Vertiguard scores
Number of subjects: 220
Study: 28526048

Group type: COMPARATOR
Intervention: Injectable hydromorphone
Number of subjects: 202

Group type: COMPARATOR
Intervention: Injectable diacetylmorphine
Number of subjects: 202
Study: 25622303

Group type: EXPERIMENTAL
Intervention: High-quality foster care intervention
Number of subjects: 136
Study: 23239048

Group type: EXPERIMENTAL
Intervention: Synbiotic mixture (2.5 × 10(9) CFU live bacteria including Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium bifidum, Bifidobacterium longum, Enterococcus faecium, and 625 mg fructooligosaccharide) for 5 days
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Synbiotic mixture
Number of subjects: 209

Group type: COMPARATOR
Intervention: Control (conventional hydration therapy without synbiotic)
Number of subjects: 209
Study: 21215482

Group type: EXPERIMENTAL
Intervention: VIPER-BP intervention (intensive BP management strategy using valsartan-based therapy)
Number of subjects: 2157

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2157
Study: 18061128

Group type: EXPERIMENTAL
Intervention: Longitudinal urinary creatinine excretion data
Number of subjects: 507
Study: 16941298

Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion
Number of subjects: 253

Group type: COMPARATOR
Intervention: Transfusion of unwashed wound drainage
Number of subjects: 253
Study: 12942142

Group type: EXPERIMENTAL
Intervention: Procyclidine (15 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 10675222

Group type: EXPERIMENTAL
Intervention: London handicap scale (LHS)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Unweighted London handicap scale (U‐LHS)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Standard weighted scoring of LHS
Number of subjects: 323